The award highlights van de Winkel’s role in advancing Genmab’s position as a global leader in antibody-based therapeutics, as well as his commitment to innovation within Denmark’s thriving life sciences ecosystem. Under his leadership, Genmab has continued to expand its research capabilities and strengthen partnerships aimed at delivering transformative treatments to patients worldwide.

Jan van de Winkel emphasized the importance of collaboration and scientific curiosity in driving progress:

“I am extremely grateful to receive the CEO of the Year award from DANISH BIO - DANSK BIOTEK. Denmark has played a defining role in Genmab’s journey as the country where the company was founded and as part of a strong Danish life science ecosystem that continues to support innovation. Being recognized by Dansk Biotek makes this acknowledgment particularly meaningful.”

He further noted that the recognition reflects a broader team effort and the collective mission of the company:

“To me, it reflects the importance of curiosity, persistence, and collaboration. I strongly believe that progress in our field is driven by teams and partnerships working together to push the boundaries of what’s possible in antibody-based medicines. At Genmab, we believe that innovation in science should translate into real impact for patients.”

Van de Winkel also expressed appreciation for his colleagues, adding that the award represents shared achievements across the organization.

The CEO of the Year award from Danish Bio honors leaders who demonstrate exceptional vision, strategic execution, and impact within the biotech industry. Van de Winkel’s recognition underscores both his personal leadership and Genmab’s continued influence in shaping the future of antibody therapeutics.